Kantonsspital St.Gallen
login

publications

Martin Früh

title  
 
Sumer J, Waldeck F, Fischer N, Appenzeller C, Koster M, Früh M, albrich w. HSV-pneumonitis in a patient with lung cancer receiving check point inhibitors - a case report. Pneumonia (Nathan) 2021; 13:1.
   
Bösch M, Baty F, Rothschild S I, Tamm M, Joerger M, Früh M, Brutsche M. Tumour neoantigen mimicry by microbial species in cancer immunotherapy. Br J Cancer 2021;.
   
Schmid S, Suipyte J, Herrmann C, Mousavi M, Hitz F, Früh M. Does progress achieved in the treatment of patients with metastatic non-small-cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland. Eur J Cancer Care (Engl) 2020; 29:e13206.
   
Metaxas Y, Früh M, Eboulet E I, Grosso F, Pless M, Zucali P A, Ceresoli G L, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C, Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos R, Swiss Group for Clinical Cancer Research (SAKK) . Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16). Ann Oncol 2020; 31:495-500.
   
Schmid S, Mauti L A, Friedlaender A, Blum V, Rothschild S I, Bouchaab H, Frösch P, Britschgi C, König D, Wannesson L, Janthur W D, Schär S, Demmer I, Addeo A, Jochum W, Früh M. Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort. Cancer Immunol Immunother 2020; 69:1605-1613.
   
Reck M, Wehler T, Orlandi F, Nogami N, Barone C, Moro-Sibilot D, Shtivelband M, González Larriba J L, Rothenstein J, Früh M, Yu W, Deng Y, Coleman S, Shankar G, Patel H, Kelsch C, Lee A, Piault E, Socinski M A. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer. J Clin Oncol 2020; 38:2530-2542.
   
Früh M, Panje C M, Reck M, Blackhall F, Califano R, Cappuzzo F, Besse B, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruysscher D, Putora P M. Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. Lung Cancer 2020; 146:6-11.
   
Früh M, siano m. Radiation dosimetry of 18F-AzaFol: A first inhuman use of a folate receptor PET tracer. EJNMMI Research 2020; 10:.
   
Mark M, Froesch P, Eboulet E I, Addeo A, Pless M, Rothschild S I, Janthur W D, Burmeister H, Friedlaender A, Schneider M, Metaxas Y, Joerger M, Wannesson L, Schwitter M, Baudoux N, Weindler S, Biaggi-Rudolf C, Früh M, Swiss Group for Clinical Cancer Research (SAKK) . SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. Cancer Immunol Immunother 2020;.
   
Schmid S, Früh M, Peters S. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?. Lancet Oncol 2020; 21:320-322.
   
Putora P M, Fischer G F, Früh M, Califano R, Faivre-Finn C, Van Houtte P, McDonald F, Nestle U, Dziadziuszko R, Le Pechoux C, Ramella S, Belderbos J, Slotman B J, Troost E G C, Peeters S, Widder J, Pöttgen C, Reck M, Blackhall F, Cappuzzo F, Besse B, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruysscher D. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. Radiother Oncol 2020; 149:84-88.
   
Britschgi C, Addeo A, Rechsteiner M, Delaloye R, Früh M, Metro G, Banini M, Gautschi O, Rothschild S I, Wild P J, Banna G L, Curioni-Fontecedro A. Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. Front Oncol 2020; 10:1299.
   
Gnesin S, Müller J, Burger I A, Meisel A, Siano M, Früh M, Choschzick M, Müller C, Schibli R, Ametamey S M, Kaufmann P A, Treyer V, Prior J O, Schaefer N. Radiation dosimetry of F-AzaFol: A first in-human use of a folate receptor PET tracer. EJNMMI Res 2020; 10:32.
   
Mazières J, Drilon A, Lusque A, Mhanna L, Cortot A B, Mezquita L, Thai A A, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng T L, Gounant V, Popat S, Diebold J, Sabari J, Zhu V W, Rothschild S I, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten R D, Wakelee H, Camidge D R, Zalcman G, Novello S, Ou S I, Milia J, Gautschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2019;.
   
Trefny M P, Rothschild S I, Uhlenbrock F, Rieder D, Kasenda B, Stanczak M A, Berner F, Kashyap A S, Kaiser M, Herzig P, Poechtrager S, Thommen D S, Geier F, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz K D, Zippelius A, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clin Cancer Res 2019; 25:3026-3034.
   
Früh M, Peters S. EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in Non-Small Cell Lung Cancer. Ann Oncol 2019;.
   
Molina-Vila M A, Stahel R A, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Curioni Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Rosell R. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. J Thorac Oncol 2019; 15:416-425.
   
Putora P M, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, Brien M O, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost E G C, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman B J. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiother Oncol 2019; 135:74-77.
   
Putora P M, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O' Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost E G C, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman B J. Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]. Radiother Oncol 2019; 141:332.
   
schmid s, Aeppli S, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort. lungcancer 2019;.
   
schmid s, Klingbiel D, Aeppli S, Britschgi C, Gautschi O, Pless M, Rothschild S, Wannesson L, Janthur W, Foerbs D, Demmer I, Jochum W, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. Lung Cancer 2019; 130:149-155.
   
Putora P M, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost E G C, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiother Oncol 2019; 133:163-166.
   
Papachristofilou A, Hipp M M, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geißler M, Griesinger F, Kallen K J, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong H S, Koch S D, Gnad-Vogt U, Zippelius A. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer 2019; 7:38.
   
Kresoja-Rakic J, Szpechcinski A, Kirschner M B, Ronner M, Minatel B, Martinez V D, Lam W L, Weder W, Stahel R, Früh M, Cerciello F, Felley-Bosco E. miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery. Noncoding RNA 2019; 5:.
   
Schett A, Rothschild S I, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Joerger M. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer Chemother Pharmacol 2019; 85:121-131.
   
Früh M, Peters S. Genomic Features of Response to Combination Immunotherapy in Lung Cancer. Cancer Cell 2018; 33:791-793.
   
Früh M, Peters S. EML4-ALK Variant Affects ALK Resistance Mutations. J Clin Oncol 2018; 36:1257-1259.
   
Mousavi S M, schmid s, Cerny T, Früh M. Lung cancer and smoking trends in the young in Switzerland: a study based on data of the National Institute for Cancer Epidemiology and Registration and of the Swiss Health Surveys. Swiss Med Wkly 2018; 148:w14708.
   
. Immune checkpoint inhibitors and small cell lung cancer: what’s new?. Journal of theoracic disease 2018; 10:1503-1508.
   
schmid s, Früh M. Immune checkpoint inhibitors and small cell lung cancer: what's new?. J Thorac Dis 2018; 10:S1503-S1508.
   
Früh M, Betticher D C, Stupp R, Xyrafas A, Peters S, Ris H B, Mirimanoff R O, Ochsenbein A F, Schmid R, Matzinger O, Stahel R A, Weder W, Guckenberger M, Rothschild S I, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol 2018;.
   
Metaxas Y, Rivalland G, Klingbiel D, Kao S, schmid s, Nowak A K, Gautschi O, Bartnick T, Hughes B G, Bouchaab H, Rothschild S, Pavlakis N, Wolleb S, Petrausch U, O'Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, Mauti L, John T. Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. J Thorac Oncol 2018;.
   
Radovic M, Kanesvaran R, Rittmeyer A, Früh M, Minervini F, Glatzer M, Putora P M. Multidisciplinary treatment of lung cancer in older patients: A review. J Geriatr Oncol 2018; 10:405-410.
   
schmid s, Diem S, Li Q, Krapf M, Flatz L, Leschka S, Desbiolles L, Klingbiel D, Jochum W, Früh M. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Immunother 2018;.
   
Griesinger F, Radke S, Lüers A, Deschler-Baier B, Kimmich M, Sebastian M, Schulz C, Brugger W, Wiewrodt R, Pirker R, Früh M, Gautschi O, Wolf J. [Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]. Pneumologie 2018; 72:774-781.
   
Diem S, Fässler M, Ali O H, siano m, Niederer R, Berner F, Roux G A, Ackermann C J, schmid s, Güsewell S, Früh M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Manag Res 2018; 10:5537-5544.
   
Baty F, Joerger M, Früh M, Klingbiel D, Zappa F, Brutsche M. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. J Transl Med 2017; 15:66.
   
Ess S M, Herrmann C, Frick H, Krapf M, Cerny T, Jochum W, Früh M. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices. Eur J Cancer Care (Engl) 2017;.
   
Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix S P, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames D S, Molina-Vila M A, Stahel R A, BELIEF collaborative group . Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med 2017; 5:435-444.
   
Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A J, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017; 111:176-181.
   
Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot J M, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier A C, Tomasini P, Dansin E, Pérol M, Campana M, Gautschi O, Früh M, Fumet J D, Audigier-Valette C, Couraud S, Dalle S, Leccia M T, Jaffro M, Collot S, Prévot G, Milia J, Mazières J. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 2017; 50:.
   
Glatzer M, Rittmeyer A, Müller J, Opitz I, Papachristofilou A, Psallidas I, Früh M, Born D, Putora P M. Treatment of limited disease small cell lung cancer: the multidisciplinary team. Eur Respir J 2017; 50:.
   
siano m, Molinari F, Martin V, Mach N, Früh M, Freguia S, Corradino I, Ghielmini M, Frattini M, Espeli V. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer. Oncologist 2017;.
   
Parra-Guillen Z P, Berger P B, Haschke M, Donzelli M, Winogradova D, Pfister B, Früh M, gillessen s, Krähenbühl S, Kloft C, Joerger M. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. Basic Clin Pharmacol Toxicol 2017; 121:309-315.
   
Gautschi O, Milia J, Filleron T, Wolf J, Carbone D P, Owen D, Camidge R, Narayanan V, Doebele R C, Besse B, Remon-Masip J, Jänne P A, Awad M M, Peled N, Byoung C C, Karp D D, Van Den Heuvel M, Wakelee H A, Neal J W, Mok T S K, Yang J C H, Ou S H I, Pall G, Froesch P, Zalcman G, Gandara D R, Riess J W, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild S I, Shih J Y, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol 2017; 35:1403-1410.
   
Glatzer M, Schmid S, Radovic M, Früh M, Putora P M. The role of radiation therapy in the management of small cell lung cancer. Breathe (Sheff) 2017; 13:e87-e94.
   
Peters S, Gettinger S, Johnson M L, Jänne P A, Garassino M C, Christoph D, Toh C K, Rizvi N A, Chaft J E, Carcereny Costa E, Patel J D, Chow L Q M, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd F A, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol 2017; 35:2781-2789.
   
Gautschi O, Rothschild S I, Li Q, Matter-Walstra K, Zippelius A, Betticher D C, Früh M, Stahel R A, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein A F, . Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clin Lung Cancer 2016;.
   
Neumair P, Joos L, Warschkow R, Dutly A, Ess S, Hitz F, Früh M, Brutsche M, Baty F, Krähenbühl S, cerny t, Joerger M. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. Lung Cancer 2016; 100:38-44.
   
schmid s, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, reichegger h, Jochum W, Diebold J, Früh M. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). J Thorac Oncol 2016;.
   
Baty F, Joerger M, Früh M, Brutsche M. 61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC). J Thorac Oncol 2016; 11:S81.
   
Putora P M, Szentesi K, Glatzer M, Rodriguez R, Müller J, Baty F, Früh M. SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer. Oncol Res Treat 2016; 39:681-686.
   
Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French L E, Speiser D E, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology 2016; 5:e1231292.
   
bickel a, koneth i, Enzler-Tschudy A, Neuweiler J, Flatz L, Früh M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC Cancer 2016; 16:656.
   
Früh M, Ris H B, Xyrafas A, Peters S, Mirimanoff R O, Gautschi O, Pless M, Stupp R. Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial. Ann Oncol 2016; 27:1971-3.
   
reichegger h, Jochum W, Förbs D, Hader C, Früh M. Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung. Oncol Res Treat 2016; 39:461-3.
   
Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol 2015; 27:281-6.
   
Gautschi O, Mach N, Rothschild S I, Li Q, Stahel R A, Zippelius A, Cathomas R, Früh M, Betticher D C, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut E O, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A F, Swiss Group for Clinical Cancer Research . Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clin Lung Cancer 2015; 16:358-65.
   
Koeberle D, Betticher D C, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Anchisi S, Moosmann P, Kollar A, Saletti P, Roth A, Früh M, Kueng M, Popescu R A, Schacher S, Hess V, Herrmann R. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol 2015; 26:709-14.
   
Stahel R A, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar C B, Eckhardt K, Schmid R A, Aebersold D M, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik L F, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 2015; 16:1651-8.
   
Putora P M, Ess S, Panje C, Hundsberger T, van Leyen K, Plasswilm L, Früh M. Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC). Clin Exp Metastasis 2015; 32:143-9.
   
Pless M, Stupp R, Ris H B, Stahel R A, Weder W, Thierstein S, Gerard M A, Xyrafas A, Früh M, Cathomas R, Zippelius A, Roth A, Bijelovic M, Ochsenbein A, Meier U R, Mamot C, Rauch D, Gautschi O, Betticher D C, Mirimanoff R O, Peters S, . Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 2015; 386:1049-56.
   
Gautschi O, Milia J, Cabarrou B, Bluthgen M V, Besse B, Smit E F, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Curioni-Fontecedro A, Huret B, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol 2015; 10:1451-7.
   
Diem S, Ess S, cerny t, Früh M, Hitz F. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. Eur J Intern Med 2014; 25:577-82.
   
Joerger M, Baty F, Früh M, Droege C, Stahel R A, Betticher D C, von Moos R, Ochsenbein A, Pless M, Gautschi O, Rothschild S, Brauchli P, Klingbiel D, Zappa F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer 2014; 85:306-13.
   
Leitner C, Von Moos R, Früh M, Mark M, Cathomas R. Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib. Cancer Treatment Communications 2014; 2:4-7.
   
Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch S D, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen K J, Gnad-Vogt U, Zippelius A. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 2014; 14:748.
   
Baty F, Rothschild S, Früh M, Betticher D, Dröge C, Cathomas R, Rauch D, Gautschi O, Bubendorf L, Crowe S, Zappa F, Pless M, Brutsche M, Swiss Group for Clinical Cancer Research . EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. PLoS ONE 2013; 8:e72966.
   
Diem S, Früh M, Rodriguez R, Liechti P, Rothermundt C. EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report. Case Rep Oncol 2013; 6:316-9.
   
Schwitter M, Früh M, Schneider T, Kluckert J T, Rodriguez R, Brutsche M. Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested?. Oncology 2013; 2013:263-268.
   
Schwitter M, Rodriguez R, Schneider T, Kluckert T, Brutsche M, Früh M. Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested?. Case Rep Oncol 2013; 6:263-8.
   
Putora P M, Früh M, Müller J. FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma. Respirology 2013; 18:734-5.
   
Früh M, Besrour H, gillessen s, Joerger M, Hitz F, Savidan A, cerny t, Ess S. Management of elderly patients with advanced non-small cell lung cancer: a single-center experience. Chemotherapy 2013; 59:42-50.
   
Früh M, Cathomas R, siano m, Tscherry G, Zippelius A, Mamot C, Erdmann A, Krasniqi F, Rauch D, Simcock M, Küttel E, Fustier P, Pless M, Swiss Group for Clinical Cancer Research . Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). Clin Lung Cancer 2012; 14:34-9.
   
Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2012; 22:567-574.
   
Joerger M, Matter-Walstra K, Früh M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis. Ann Oncol 2012; 22:567-574.
   
hochstrasser a, Benz G, Joerger M, templeton a, Brutsche M, Früh M. Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?. Chemotherapy 2012; 58:84-88.
   
Putora P M, Schneider T, Rodriguez R, Früh M. Targeted therapy in non-small cell lung cancer. Breathe 2012; 8:206-215.
   
Rossi A, Di Maio M, Chiodini P, Rudd R, Okamoto H, Skarlos D, Früh M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee S. Carboplatin- or Cisplatin-based chemotherapy in first-line treatement of scmall cell lung cancer: The COCIS individual patient data meta-analysis. J Clin Oncol 2012;1692-1698.
   
Früh M, Kacsir B, Ess S, cerny t, Rodriguez R, Plasswilm L. Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation? A single center experience. Strahlenther Onkol 2011; 187:561-7.
   
Stahel R, Thatcher N, Früh M, Le Péchoux C, Postmus P E, Sorensen J B, Felix E, Panel members . 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Ann Oncol. 2011; 22:1973-1980.
   
bastian s, Clerici T, Neuweiler J, cerny t, Früh M. Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature. Onkologie 2011; 34:665-70.
   
Putora P M, Früh M. The place of radiotherapy in the palliative management of NSCLC. Breathe 2011; 8: 134-143 2011;.
   
Putora P M, Benz G, Rodriguez R, Brutsche M, Früh M. Tracheal granuloma pyogenicum with erlotinib treatment for lung cancer. Eur Respir J 2011; 38:1228-30.
   
Früh M. The search for improved systemic therapy of non-small cell lung cancer--what are today's options?. Lung Cancer 2011; 72:265-270.
   
Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2010; 22:567-74.
   
Früh M, Shepherd F. Adjuvant Cisplatin-Based Chemotherapy for Elderly. EUROPEAN JOURNAL OF CLINICAL & MEDICAL ONCOLOGY 2010;59-63.
   
D'Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E, ESMO Guidelines Working Group . Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5:v116-9.
   
Joerger M, Omlin A, cerny t, Früh M. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Current drug targets 2010; 11:37-47.
   
Cerny D, cerny t, ess s, D'Addario G, Früh M. Lung Cancer in the Canton of St. Gallen, Eastern Switzerland:. Onkologie 2009; 32:569-73.
   
Früh M, Pignon J P, Shepherd F. Review Article: Elderly patients with early non-small cell lung cancer: What are the benefits and harms of adjuvant platinum-based chemotherapy?. AJHO 2009; 8:76-79.
   
Omlin A, D'Addario G, gillessen s, cerny t, vonhessling a, Früh M. Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. Lung cancer (Amsterdam, Netherlands) 2009; 65:383-4.
   
Früh M, Rolland E, Pignon J P, Seymour L, Ding K, Tribodet H, Winton T, Le Chevalier T, Scagliotti G V, Douillard J Y, Spiro S, Shepherd F A. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3573-81.
   
Früh M, gillessen s, cerny t, Demmer-Steingruber R, D'Addario G. Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2008; 62:344-50.
   
Früh M, Zhou W, Zhai R, Su L, Heist R S, Wain J C, Nishioka N S, Lynch T J, Shepherd F A, Christiani D C, Liu G. Polymorphisms of inflammatory and metalloproteinase genes, Helicobacter pylori infection and the risk of oesophageal adenocarcinoma. British journal of cancer 2008; 98:689-92.
   
Lanz C, Früh M, Thormann W, cerny t, Lauterburg B H. Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC. Journal of separation science 2007; 30:1811-20.
   
Rodin G, Zimmermann C, Rydall A, Jones J, Shepherd F A, Moore M, Früh M, Donner A, Gagliese L. The desire for hastened death in patients with metastatic cancer. Journal of pain and symptom management 2007; 33:661-75.
   
Früh M, ruhstaller t, Neuweiler J, cerny t. Resection of skin metastases from gastric carcinoma with long-term follow-up: an unusual clinical presentation. Onkologie 2005; 28:38-40.
   
Früh M. Use of second-line biochemical and susceptibility tests for the differential identification of coryneform bacteria. Clinical Microbiology and Infection 1998; Vol. 4 June 1998:.
   
Früh M (2014). Advances in Radiotherapy for Locally Advanced NSCLC. In New Therapeutic Strategies in Lung Cancers (pp. 69-94): Springer.
   
 
page 1 of 2